Growth Hormone Treatment of Children With HIV-Associated Growth Failure
A Randomized, Open-Label Study of Recombinant Human Growth Hormone (r-hGH) in Children With HIV-Associated Growth Failure
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Listed as NCT00006143, this NA trial focuses on HIV Infections and remains completed. Sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), it has been updated 7 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Dec 2021 — Jul 2024 [monthly]
Completed NA
-
Jan 2021 — Dec 2021 [monthly]
Completed NA
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States, Bayamón, Puerto Rico, Boston, United States, Chicago, United States, Durham, United States, Fort Lauderdale, United States, Houston, United States, Jacksonville, United States, Los Angeles, United States, Miami, United States and 8 more location s